ALK and non-small cell lung carcinoma: The PROFILE 1014 and the PROFILE 1007 trials confirmed a survival superiority of crizotinib over platinum‐based chemotherapy in first‐line and second‐line therapy (after 1 platinum‐based chemotherapy regimen) for ALK‐positive NSCLC, respectively.173, 174